[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Note
April 2016

Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder

JAMA Intern Med. 2016;176(4):547-548. doi:10.1001/jamainternmed.2015.8104

The use of prostate-specific antigen (PSA) screening for prostate cancer is controversial. Various organizations have released conflicting messages regarding the use of the PSA screening test. In 2012, the US Preventive Services Task Force recommended against routine PSA screening, citing a lack of evidence regarding its benefits and known harms from prostate biopsy and overtreatment of indolent prostate cancer.1

First Page Preview View Large
First page PDF preview
First page PDF preview